- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04971018
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis Systemic Sclerosis (AVADIS)
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Conduct of study:
Entry into the study: After informed consent, patients will be randomised into two arms (active or sham stimulation). The person responsible for setting the stimulator will make the randomization via an interactive web response system (IWRS). Only this person will have the knowledge of the group allocated to the patient.
Start of ta-VNS sessions according to the 1st modality of stimulation : The patient will perform 2 stimulation sessions per day at home for 3 months. During this period a clinical research associate will contact the patient to verify that he does not encounter any problems with the stimulator. An evaluation visit will be carried out at the end of these three months by a blind physician.
Wash-out period during 1 month.
Start of ta-VNS sessions according to the 2nd modality of stimulation : The patient will perform 2 stimulation sessions per day at home for 3 months. An evaluation visit will be conducted prior to the start of the sessions and another at the end of the sessions.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sophie blaise, MD/PHD
- Phone Number: +330476767575
- Email: sblaise@chu-grenoble.fr
Study Locations
-
-
-
Grenoble, France
- Recruiting
- vascular medicine department, University hospital
-
Contact:
- Sophie Blaise, MD/phd
- Phone Number: 0476767575
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- SSc meeting ACR-EULAR (American College of Rheumatology- European League Against Rheumatism) criteria.
- Treatment by proton pump inhibitor (PPI) initiated for at least 3 months.
- Patient's written consent
- Affiliated with social security system
Exclusion Criteria:
- Patients who have previously received central or peripheral neurostimulation treatment regardless of indication.
- People equipped with an active pacemaker in the area of application of the stimulation electrodes.
- People with dermatological disease in the area of application of stimulation electrodes
- People with recent venous or arterial thrombosis (less than one month)
- People with a cochlear implant near the stimulation site
- People followed for proven heart disease
- Person who are protected under the act
- Pregnant or breastfeeding woman
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active ta-VNS
|
Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
|
Placebo Comparator: Sham ta-VNS
|
Patients will have 20-minutes stimulation sessions at home twice a day during 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of ta-VNS on Evolution of Gastrointestinal Quality of life.
Time Frame: Evolution of UCLA-SCTC-GIT 2.0 will be assessed from day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the evolution of the total score University of California, Los Angeles - Scleroderma Clinical Trial Consortium - Gastrointestinal Tract Instrument, version 2.0 ( UCLA-SCTC-GIT 2.0).
This score is specific to the SSc, assessing gastrointestinal symptoms and quality of life, validated in French.
|
Evolution of UCLA-SCTC-GIT 2.0 will be assessed from day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of ta-VNS on quality of life.
Time Frame: Evolution of sHAQ will be assessed from day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the evolution of the Health Assessment Questionnaire for scleroderma (sHAQ)
|
Evolution of sHAQ will be assessed from day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Effect of ta-VNS on flexibility of the autonomic nervous system
Time Frame: day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the evolution of heart rate variability (HRV)
|
day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Effect of ta-VNS on anxiety and Depression
Time Frame: HADS will be assessed from day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the Hospital Anxiety and Depression Scale (HADS).
HADS score ranges from 0 (better) to 42 (worse).
|
HADS will be assessed from day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Effect of ta-VNS on gastric motility
Time Frame: Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the frequency of gastric waves assessed with a electrogastrography.
|
Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Effect of ta-VNS on digestive symptomatic treatments used
Time Frame: Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups : Description of the treatments taken by patients, the evolution of their posology, the frequency of administration. |
Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Effect of ta-VNS on the number and location of digital ulcers.
Time Frame: Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the number and location of digital ulcers.
|
Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Effect of ta-VNS on Raynaud's Condition Score (RCS)
Time Frame: Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Comparison between the 2 groups of the Raynaud's Condition Score (RCS).
RCS is a 10 points scale ranging from 0 (better) to 10 (worse).
|
Day 0 to Month 3 for the first step. And from the month 4 to month 7 for the second step
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC20.363
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
AmgenEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
AmgenRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
-
Mitsubishi Tanabe Pharma America Inc.CompletedDiffuse Cutaneous Systemic SclerosisSpain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Clinical Trials on Auricular vagus nerve stimulation
-
Anna HuguenardRecruiting
-
İSMAİL CEYLANCompleted
-
Jiani WuNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteNot yet recruitingCluster Headache | Migraine in Children | Tension Headache | Migraine in Adolescence | Primary HeadacheChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingParkinson DiseaseChina
-
Cairo UniversityRecruitingStroke | Motor DisordersEgypt
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
University of MiamiRecruiting
-
Guang'anmen Hospital of China Academy of Chinese...China Association for Science and TechnologyRecruiting
-
Bahçeşehir UniversityCompletedChronic Migraine, HeadacheTurkey